TIDMIDH
RNS Number : 9484U
Immunodiagnostic Systems Hldgs PLC
02 July 2009
?
Immunodiagnostic Systems Holdings plc
New specialist assay launched for IDS-iSYS
Immunodiagnostic Systems Holdings plc ("IDS"), a leading producer of diagnostic
testing kits for the clinical and research markets, announces the launch of a
newly-developed fully-automated immunoassay for PINP, used as a bone formation
marker, to appear on the IDS-iSYS Immunoanalyser.
IDS's new fully-automated Immunoanalyser, the IDS-iSYS, was launched at the end
of February, at the same time as the launch of its automated IDS iSYS Vitamin D
assay; flagship product 25 Hydroxy Vitamin D, a test to quantify vitamin D in
patient serum or plasma. It is IDS's stated aim that throughout 2009 and into
2010/11, it will add highly complementary bone and skeletal products available
for use on IDS-iSYS, such as Parathyroid Hormone (PTH), CTX-I, N-Mid
Osteocalcin, PINP, Bone-Specific Alkaline Phosphatase (BSAP), TRAP 5B.
PINP is the second of a number of new products due to appear on the IDS-iSYS by
the end of the Financial Year 2009/2010.
About PINP (Procollagen type 1 N-terminal Propeptide)
The synthesis of type 1 collagen is a crucial step in bone formation and is the
major organic component of bone matrix. PINP is cleaved during collagen
synthesis and enters the circulation, and its quantification in human serum or
plasma therefore provides a valuable measurement of bone formation.
PINP has found a place in routine clinical use as a bone formation marker, and
is of particular value in monitoring the efficacy of expensive bone therapies
such as the parathyroid hormone (PTH) analogues such as Forteo (in the USA) or
Forsteo (in the EU) from Eli Lilly. Such analogues are used in the treatment
of osteoporosis, and can promote the growth of new bone in post--menopausal
osteoporotic women. Osteoporosis affects an estimated 44 million in the USA
alone, where osteoporosis-related fractures cost an estimated $19 billion in
2005 (Source: National Osteoporosis Foundation; www.nof.org) .
IDS has obtained a licence from the patent-holders, Orion Diagnostica Oy, Espoo,
Finland, who were the first (in 1995) to launch a commercial PINP assay onto the
In Vitro Diagnostics (IVD) market. The major benefit of the technology licensed
is the ability to determine only intact PINP in patient serum. In certain
patient groups, such as those with chronic renal failure, fragments of PINP
accumulate in the serum and can give rise to extremely high results if a less
specific assay is employed, and this can confuse clinical interpretation. We
believe the only other automated PINP method on the market suffers from this
flawed approach.
Dr Roger Duggan, Managing Director of IDS, said:
"The PINP product launched today fits exactly with our philosophy of providing
analytical excellence. It is difficult to justify the use of clinical tools that
may deliver questionable results when highly specific alternatives are within
reach, and our delivery of a fully-automated intact PINP assay will be
particularly welcomed by those working with patients with compromised renal
function. This is a welcome addition to the evolving range of products to appear
on the IDS-iSYS, and we look forward to considerable success in the
marketplace."
Enquiries:
+------------------------------------+------------------------------------+
| Immunodiagnostic Systems Holdings | Tel: 0191 519 0660 |
| Plc | |
+------------------------------------+------------------------------------+
| Roger Duggan, CEO | |
+------------------------------------+------------------------------------+
| Paul Hailes, Finance Director | |
+------------------------------------+------------------------------------+
| | |
+------------------------------------+------------------------------------+
| Brewin Dolphin Investment Banking | Tel: 0845 213 4730 |
+------------------------------------+------------------------------------+
| Andrew Emmott | |
| Sean Wyndham-Quin | |
+------------------------------------+------------------------------------+
| | |
+------------------------------------+------------------------------------+
| Walbrook PR Ltd | Tel: 020 7933 8787 |
+------------------------------------+------------------------------------+
| Paul McManus | Mob: 07980 541 893 |
+------------------------------------+------------------------------------+
| | paul.mcmanus@walbrookpr.com |
+------------------------------------+------------------------------------+
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRACKDKBPBKDFOK
|